» Articles » PMID: 30643152

Counting Circulating Endothelial Cells in Allo-HSCT: an Ad Hoc Designed Polychromatic Flowcytometry-based Panel Versus the CellSearch System

Abstract

Physio-pathologic interrelationships between endothelial layer and graft-versus-host disease (GVHD) have been described leading to assess the entity "endothelial GVHD" as the early step for clinical manifestations of acute GVHD. The availability of the CellSearch system has allowed us to monitor Circulating Endothelial Cells (CEC) changes in allogeneic hematopoietic stem cell transplantation (allo-HSCT) as useful tool to help clinicians in GVHD diagnostic definition. We have compared CEC counts generated by an ad hoc designed polychromatic-flowcytometry (PFC) Lyotube with those of the CellSearch system. CEC were counted in parallel at 5 timepoints in 50 patients with malignant hematologic disorders undergoing allo-HSCT (ClinicalTrials.gov, NCT02064972). Spearman rank correlation showed significant association between CEC values at all time points (p = 0.0001). The limits of agreement was demonstrated by Bland Altman plot analysis, showing bias not significant at T1, T3, T4, while at T2 and T5 resulted not estimable. Moreover, Passing Bablok regression analysis showed not significant differences between BD Lyotube and CellSearch system. We show that CEC counts, generated with either the CellSearch system or the PFC-based panel, have a superimposable kinetic in allo-HSCT patients and that both counting procedures hold the potential to enter clinical routine as a suitable tool to assist clinicians in GVHD diagnosis.

Citing Articles

Establishment and clinical value of a circulating tumor cell system based on a multi-site immune lipid magnetic sphere technique in laryngopharyngeal head and neck tumors.

Chen W, Lin Q, Wang D, Xie W, Huang C, Fan W Am J Cancer Res. 2025; 15(1):19-31.

PMID: 39949932 PMC: 11815362. DOI: 10.62347/MVRG3697.


Adjuvant Treatment with Empagliflozin or Semaglutide Increases Endothelial Progenitor Cells in Subjects with Well-Controlled Type 1 Diabetes Mellitus.

Preloznik Navodnik M, Rebersek K, Klinar K, Janez A, Podgornik H Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852169 PMC: 11764144. DOI: 10.3390/cimb47010054.


Liquid Biopsy Instrument for Ultra-Fast and Label-Free Detection of Circulating Tumor Cells.

Zhu S, Zhu Z, Ni C, Zhou Z, Chen Y, Tang D Research (Wash D C). 2024; 7:0431.

PMID: 39050821 PMC: 11266806. DOI: 10.34133/research.0431.


Circulating Endothelial Cells: A New Possible Marker of Endothelial Damage in Kawasaki Disease, Multisystem Inflammatory Syndrome in Children and Acute SARS-CoV-2 Infection.

Fabi M, Petrovic B, Andreozzi L, Corinaldesi E, Filice E, Biagi C Int J Mol Sci. 2022; 23(17).

PMID: 36077506 PMC: 9456219. DOI: 10.3390/ijms231710106.


Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?.

Lia G, Giaccone L, Leone S, Bruno B Front Immunol. 2021; 12:641427.

PMID: 34093530 PMC: 8170404. DOI: 10.3389/fimmu.2021.641427.


References
1.
Hill J, Zalos G, Halcox J, Schenke W, Waclawiw M, Quyyumi A . Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348(7):593-600. DOI: 10.1056/NEJMoa022287. View

2.
Almici C, Skert C, Verardi R, Di Palma A, Bianchetti A, Neva A . Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation. 2014; 98(7):706-12. DOI: 10.1097/TP.0000000000000385. View

3.
Paczesny S . Discovery and validation of graft-versus-host disease biomarkers. Blood. 2012; 121(4):585-94. PMC: 3557644. DOI: 10.1182/blood-2012-08-355990. View

4.
Goon P, Boos C, Stonelake P, Blann A, Lip G . Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost. 2006; 96(1):45-52. DOI: 10.1160/TH06-04-0185. View

5.
Pidala J . Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control. 2011; 18(4):268-76. DOI: 10.1177/107327481101800407. View